Adalimumab BS Subcutaneous Injection 40mg Syringe 0.4mL "CTNK" (アダリムマブBS皮下注40mgシリンジ0.4mL「CTNK」)

Država: Japonska

Jezik: angleščina

Source: すりの適正使用協議会 RAD-AR Council, Japan

Aktivna sestavina:

Adalimumab(genetical recombination) [adalimumab biosimilar 4]

Dostopno od:

NIPPON KAYAKU

INN (mednarodno ime):

Adalimumab(genetical recombination) [adalimumab biosimilar 4]

Farmacevtska oblika:

colorless to faintly yellowish brown and limpid or slightly opalescent injectable solution in prefilled syringe

Navodilo za uporabo

Drug Information Sheet("Kusuri-no-Shiori")
Self-injection
Published: 11/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
ADALIMUMAB BS SUBCUTANEOUS INJECTION
40MG SYRINGE 0.4ML "CTNK"
ACTIVE INGREDIENT:
Adalimumab(genetical recombination) [adalimumab
biosimilar 4]
DOSAGE FORM:
colorless to faintly yellowish brown and limpid or slightly
opalescent injectable solution in prefilled syringe
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine suppresses function of TNF (tumor necrosis factor) -α,
which is one of the
possible primary causative substances in rheumatoid arthritis,
psoriasis, ankylosing
spondylitis, juvenile idiopathic arthritis, Crohn's disease and
ulcerative colitis. TNF is one of
the cytokines existing inside of the body even in a healthy state, and
involved in activities of
immunity and development of inflammation or pain. It is usually used
to treat rheumatoid
arthritis (including prevention of structural joint damage) and
diseases described below with
inadequate response to conventional therapies: active
polyarticular-juvenile idiopathic
arthritis; psoriasis vulgaris/psoriasis arthritis/pustular psoriasis;
ankylosing spondylitis;
intestinal Behcet's disease; non-infectious intermediate/posterior
uveitis or panuveitis; and
moderate to severe ulcerative colitis. It is also used for inducing
clinical remission and
maintenance therapy in patients with moderately to severely active
Crohn's disease.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you hav